# Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

Study · id `cardio:ct-nct02330406` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02330406](<https://clinicaltrials.gov/study/NCT02330406>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02330406

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.

## Technical summary

Registry record NCT02330406. Randomized; double masking; primary purpose treatment. Start 2015-04 (actual); primary completion 2018-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 353 participants (enrolled count; ClinicalTrials.gov record NCT02330406, source copy `cardio:ctgov-nct02330406-2019-08-28`, retrieved 2026-10-26)
- Started: 2015-04 (actual) (ClinicalTrials.gov record NCT02330406, source copy `cardio:ctgov-nct02330406-2019-08-28`, retrieved 2026-10-26)
- Primary completion: 2018-01 (actual) (ClinicalTrials.gov record NCT02330406, source copy `cardio:ctgov-nct02330406-2019-08-28`, retrieved 2026-10-26)
- Completion: 2019-03 (actual) (ClinicalTrials.gov record NCT02330406, source copy `cardio:ctgov-nct02330406-2019-08-28`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02330406, source copy `cardio:ctgov-nct02330406-2019-08-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02330406-2019-08-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial
- Acronym: REASON
- Condition: Dipeptidyl-Peptidase 4 Inhibitors
- Condition: LDL Cholesterol
- Condition: Glycosylated Hemoglobin
- Condition: Diabetes Mellitus
- Condition: Coronary Disease
- Intervention (Drug): Anagliptin
- Intervention (Drug): Sitagliptin
- Lead sponsor: Institute for Clinical Effectiveness, Japan
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial (`cardio:pubmed-31189978`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial (`cardio:pubmed-31733647`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy (`cardio:pubmed-32539832`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 799da9da55cb83255b92cfc291d2abd1df6988a8193ee59f4a4c2ce66224ab27
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
